Log in

NASDAQ:HALOHalozyme Therapeutics Competitors & Alternatives

$27.90
-0.08 (-0.29 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.80
Now: $27.90
$28.29
50-Day Range
$22.82
MA: $25.07
$28.51
52-Week Range
$12.71
Now: $27.90
$29.34
Volume691,600 shs
Average Volume1.42 million shs
Market Capitalization$3.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84

Competitors

Halozyme Therapeutics (NASDAQ:HALO) Vs. AMGN, GILD, CELG, VRTX, REGN, and BIIB

Should you be buying HALO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Halozyme Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB).

Halozyme Therapeutics (NASDAQ:HALO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Halozyme Therapeutics and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$195.99 million19.33$-72,240,000.00($0.50)-55.80
Amgen$23.36 billion6.30$7.84 billion$14.8216.87

Amgen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Halozyme Therapeutics and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme Therapeutics-48.75%-48.92%-17.36%
Amgen32.03%90.75%15.44%

Analyst Ratings

This is a breakdown of recent ratings for Halozyme Therapeutics and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics02802.80
Amgen1111602.54

Halozyme Therapeutics currently has a consensus price target of $29.80, suggesting a potential upside of 6.81%. Amgen has a consensus price target of $246.08, suggesting a potential downside of 1.58%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than Amgen.

Volatility and Risk

Halozyme Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Insider and Institutional Ownership

95.4% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of Amgen shares are owned by institutional investors. 2.6% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Amgen beats Halozyme Therapeutics on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Volatility and Risk

Gilead Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.

Valuation & Earnings

This table compares Gilead Sciences and Halozyme Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion4.28$5.39 billion$6.1412.49
Halozyme Therapeutics$195.99 million19.33$-72,240,000.00($0.50)-55.80

Gilead Sciences has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 95.4% of Halozyme Therapeutics shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences21.84%35.44%12.84%
Halozyme Therapeutics-48.75%-48.92%-17.36%

Analyst Ratings

This is a summary of current recommendations for Gilead Sciences and Halozyme Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences3151002.25
Halozyme Therapeutics02802.80

Gilead Sciences currently has a consensus target price of $79.6538, suggesting a potential upside of 3.88%. Halozyme Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 6.81%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Halozyme Therapeutics on 8 of the 14 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Insider and Institutional Ownership

71.7% of Celgene shares are held by institutional investors. Comparatively, 95.4% of Halozyme Therapeutics shares are held by institutional investors. 0.4% of Celgene shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Celgene and Halozyme Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celgene$15.28 billion5.04$4.05 billion$7.6114.22
Halozyme Therapeutics$195.99 million19.33$-72,240,000.00($0.50)-55.80

Celgene has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Celgene and Halozyme Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celgene06002.00
Halozyme Therapeutics02802.80

Celgene currently has a consensus target price of $105.60, indicating a potential downside of 2.44%. Halozyme Therapeutics has a consensus target price of $29.80, indicating a potential upside of 6.81%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Celgene.

Volatility & Risk

Celgene has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.

Profitability

This table compares Celgene and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celgene34.63%78.15%18.54%
Halozyme Therapeutics-48.75%-48.92%-17.36%

Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Volatility and Risk

Halozyme Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

95.4% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 2.6% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Halozyme Therapeutics and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics02802.80
Vertex Pharmaceuticals082012.76

Halozyme Therapeutics currently has a consensus target price of $29.80, indicating a potential upside of 6.81%. Vertex Pharmaceuticals has a consensus target price of $285.1154, indicating a potential upside of 0.10%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Halozyme Therapeutics and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$195.99 million19.33$-72,240,000.00($0.50)-55.80
Vertex Pharmaceuticals$4.16 billion17.74$1.18 billion$4.2966.39

Vertex Pharmaceuticals has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Halozyme Therapeutics and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme Therapeutics-48.75%-48.92%-17.36%
Vertex Pharmaceuticals31.35%25.69%18.50%

Summary

Vertex Pharmaceuticals beats Halozyme Therapeutics on 9 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Regeneron Pharmaceuticals and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0121412.59
Halozyme Therapeutics02802.80

Regeneron Pharmaceuticals currently has a consensus price target of $573.2593, indicating a potential downside of 6.92%. Halozyme Therapeutics has a consensus price target of $29.80, indicating a potential upside of 6.81%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than Regeneron Pharmaceuticals.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals28.56%24.94%18.81%
Halozyme Therapeutics-48.75%-48.92%-17.36%

Insider and Institutional Ownership

68.1% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.4% of Halozyme Therapeutics shares are owned by institutional investors. 11.3% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Halozyme Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion8.62$2.12 billion$21.4728.69
Halozyme Therapeutics$195.99 million19.33$-72,240,000.00($0.50)-55.80

Regeneron Pharmaceuticals has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Halozyme Therapeutics on 10 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Profitability

This table compares Biogen and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen40.76%49.22%24.26%
Halozyme Therapeutics-48.75%-48.92%-17.36%

Insider & Institutional Ownership

87.3% of Biogen shares are held by institutional investors. Comparatively, 95.4% of Halozyme Therapeutics shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Biogen and Halozyme Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen518902.13
Halozyme Therapeutics02802.80

Biogen currently has a consensus price target of $307.75, suggesting a potential upside of 11.29%. Halozyme Therapeutics has a consensus price target of $29.80, suggesting a potential upside of 6.81%. Given Biogen's higher probable upside, research analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.

Earnings and Valuation

This table compares Biogen and Halozyme Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion3.14$5.89 billion$33.578.24
Halozyme Therapeutics$195.99 million19.33$-72,240,000.00($0.50)-55.80

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Biogen has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.

Summary

Biogen beats Halozyme Therapeutics on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.2$250.04-0.4%$146.50 billion$23.36 billion19.60
Gilead Sciences logo
GILD
Gilead Sciences
2.0$76.68-0.5%$95.73 billion$22.45 billion19.71Analyst Revision
Celgene logo
CELG
Celgene
1.7$108.24-0.0%$77.04 billion$15.28 billion14.22
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
1.4$284.82-3.4%$76.34 billion$4.16 billion49.36
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$615.88-0.8%$68.31 billion$7.86 billion30.95
Biogen logo
BIIB
Biogen
1.9$276.52-0.9%$45.51 billion$14.38 billion8.53Analyst Report
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$174.35-3.9%$29.98 billion$916.71 million-92.74
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$108.82-0.3%$24.03 billion$4.99 billion10.25Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$124.40-1.3%$22.80 billion$1.70 billion203.93
Incyte logo
INCY
Incyte
1.4$100.56-4.2%$22.77 billion$2.16 billion-57.46
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$152.74-6.2%$18.72 billion$219.75 million-19.02
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$92.08-0.7%$13.80 billion$876.29 million-118.05Analyst Upgrade
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$129.69-1.4%$12.12 billion$788.10 million70.48
Immunomedics logo
IMMU
Immunomedics
1.9$39.97-3.4%$9.54 billion$290,000.00-21.84
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$61.04-1.7%$8.65 billion$1.12 billion55.49
Exelixis logo
EXEL
Exelixis
1.8$23.86-4.5%$7.65 billion$967.78 million25.66
Repligen logo
RGEN
Repligen
1.4$122.51-3.0%$6.69 billion$270.24 million272.25
Novavax logo
NVAX
Novavax
1.5$104.32-9.5%$5.47 billion$18.66 million-25.20Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$115.95-1.3%$5.17 billion$1.45 billion9.67
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.4$91.33-3.2%$4.94 billion$1.11 billion70.25
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$33.44-2.6%$4.03 billion$23.87 million-11.94
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.04-3.3%$4.00 billion$182.24 million-11.57Insider Selling
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$56.57-5.5%$3.69 billion$36.13 million-51.90Insider Selling
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$63.81-3.3%$3.32 billion$806.43 million-9.88
Alkermes logo
ALKS
Alkermes
1.3$19.03-3.5%$3.13 billion$1.17 billion-21.63
Opko Health logo
OPK
Opko Health
1.7$3.87-3.9%$2.69 billion$901.90 million-8.06
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$113.56-1.3%$1.85 billion$120.28 million-33.01
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$99.78-4.1%$1.60 billionN/A-14.65
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.03-1.7%$1.57 billion$428.41 million18.92
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.2$10.26-4.2%$1.53 billion$102.43 million-12.36
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$45.09-2.7%$1.49 billion$252 million-4.21
Innoviva logo
INVA
Innoviva
0.9$13.44-0.1%$1.36 billion$261.02 million7.86
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$4.95-9.9%$958.74 million$48.83 million-5.27
Myriad Genetics logo
MYGN
Myriad Genetics
1.4$11.40-0.6%$870.12 million$851.10 million-5.70
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.51-1.8%$798.31 million$35.22 million-4.62
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.22-2.4%$753.43 million$82.27 million-7.28
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.26-3.4%$722.16 million$150,000.00-4.66
Codexis logo
CDXS
Codexis
1.5$11.46-3.8%$676.35 million$68.46 million-45.84Analyst Upgrade
Agenus logo
AGEN
Agenus
1.5$3.54-7.1%$634.39 million$150.05 million-2.85
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.36-1.1%$626.23 million$227.19 million5.31Heavy News Reporting
Molecular Templates logo
MTEM
Molecular Templates
1.6$12.14-6.5%$580.31 million$22.27 million-5.59
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.37-3.9%$509.08 million$143.01 million-0.89
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.9$63.03-0.3%$464.27 million$38.19 million18.93
Geron logo
GERN
Geron
1.2$2.15-0.5%$437.13 million$460,000.00-5.51
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.16-5.7%$370.38 million$109.33 million-2.63Analyst Downgrade
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10-0.0%$355.05 million$34.99 million-5.32High Trading Volume
MannKind logo
MNKD
MannKind
1.9$1.65-7.9%$351.68 million$63.04 million-7.17
PDL BioPharma logo
PDLI
PDL BioPharma
1.2$2.71-3.7%$320.17 million$54.76 million-2.88
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$2.16-17.6%$300.05 million$59.29 million-13.50High Trading Volume
Unusual Options Activity
Heavy News Reporting
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.9$11.15-3.6%$260.51 million$3.57 million-3.77
This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.